Union Bancaire Privee UBP SA Has $2.21 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Union Bancaire Privee UBP SA boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 291.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,576 shares of the company's stock after acquiring an additional 25,734 shares during the period. Union Bancaire Privee UBP SA's holdings in Novo Nordisk A/S were worth $2,213,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. GQG Partners LLC increased its holdings in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $404,910,000. Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after acquiring an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP bought a new position in Novo Nordisk A/S during the 4th quarter worth approximately $158,657,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on NVO shares. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Friday, June 6th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Down 1.4%

Shares of NVO traded down $1.15 during midday trading on Friday, hitting $79.90. The stock had a trading volume of 7,465,072 shares, compared to its average volume of 7,025,617. The firm has a market cap of $358.57 billion, a price-to-earnings ratio of 24.29, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a 50 day simple moving average of $66.93 and a two-hundred day simple moving average of $80.00. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.